natgillin/translations-raw huggingface dataset:
An antibody that binds to human CD37 and has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:26. 
Protutijelo, naznačeno time, da se veže na ljudski CD37 i ima jaki lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:24 i slabi lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:26.
The DNA molecule of claim 11, wherein said variable heavy chain encoding region is fused to a region encoding a constant heavy chain of human origin, preferably said human constant heavy chain is IgG1 and preferably said human constant heavy chain has one or more substitutions in the Fc region. 
DNK-molekula prema zahtjevu 11, naznačena time, da navedeno područje koje kodira varijabilni jaki lanac je staljeno na područje koje kodira konstantni jaki lanac iz ljudskog izvora, dok spomenuti ljudski konstantni jaki lanac je poželjno IgG1 i spomenuti ljudski konstantni jaki lanac poželjno ima jednu ili više supstitucija u Fc-području.
The pharmaceutical composition of claim 19, further comprising one or more additional therapeutic agents. 
Farmaceutski sastav prema zahtjevu 19, naznačen time, da nadalje obuhvaća jedno ili više terapeutskih sredstava.
The pharmaceutical composition of claim 20, wherein said one or more additional therapeutic agents are agents that target the B cell antigen CD20. 
Farmaceutski sastav prema zahtjevu 20, naznačen time, da navedeni jedno ili više terapeutskih sredstava su sredstva koja ciljaju na antigen CD20 od B-stanice.
The pharmaceutical composition of claim 19 to 21 for use in depleting B cells that express CD37 on their surface. 
Farmaceutski sastav prema zahtjevima od 19 do 21, naznačen time, da se upotrebljava u iscrpljivanju B-stanica koje izražavaju CD37 na svojoj površini.
The pharmaceutical composition of claim 19 to 21 for use in curing B cell malignancies or autoimmune or inflammatory diseases that involve B cells in their pathology, preferably said B cell malignancy is selected from B cell non-Hodgkins lymphoma, B cell chronic lymphocytic leukemia and multiple myeloma. 
Farmaceutski sastav prema zahtjevima od 19 do 21, naznačen time, da se upotrebljava za ozdravljenje B-stanica od malignih bolesti ili autoimunih bolesti ili upalnih bolesti, koje uključuju B-stanicu u njihovoj patologiji, a poželjno su maligne bolesti B-stanice odabrane od sljedećih: non-Hodgkin-limfom B-stanice, kronična limfocitna leukemija B-stanice i multipli mijelom.
A compound according to any one of claims 1 to 6, wherein R3 and R4 together with the nitrogen atom to which they are attached form heterocyclyl or substituted heterocyclyl, wherein heterocyclyl is piperidinyl, pyrrolidinyl, azetidinyl or 2-oxa-6-azaspiro[3.3]heptyl, and wherein substituted heterocyclyl is heterocyclyl substituted with one to four substituents independently selected from alkyl, halogen, hydroxyl, hydroxyalkyl and alkoxyalkyl. 
Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da R3 i R4 zajedno s dušikovim atomom na kojega su priključeni, tvore heterociklil ili supstituirani heterociklil, pri čemu heterociklil je piperidinil, pirolidinil, azetidinil ili 2-oksa-6-aza-spiro[3.3]heptil, i pritom supstituirani heterociklil je heterociklil supstituiran s jednim do četiri supstituenta neovisno odabrana od sljedećih: alkil, halogen, hidroksil, hidroksialkil i alkoksialkil.
the reaction of a compound of formula (A), a tautomer thereof or a mixture of tautomers thereof in the presence of a halogenation reagent and optionally with a base; or 
reakcija spoja formule (A), njegovog tautomera ili mješavine njegovih tautomera [image] u prisutnosti halogenacijskog reagensa i po želji s lužinom; ili
the reaction of a compound of formula (B) in the presence of NHR3R4 and optionally with a base; 
reakcija spoja formule (B) [image] u prisutnosti NHR3R4 i po želji s lužinom;
A mixed turf (1) as claimed in one or more of the preceding claims, wherein the arrangement density in the soil of said synthetic filaments (5) is less than 10% to 30% of the arrangement density of said natural grass (3). 
Mješoviti travnjak (1) prema jednom ili više prethodnih zahtjeva, naznačen time da su sintetička vlakna (5) manje gustoće rasporeda u tlu za iznos koji odgovara između 10% i 30% u usporedbi s gustoćom rasporeda prirodne trave (3).
A mixed turf (1) as claimed in one or more of the preceding claims disposed on a soil (10) comprising: an upper layer (7), disposed on said support (4), and having a thickness included between 2 cm and 4 cm. 
Mješoviti travnjak (1) prema jednom ili više prethodnih zahtjeva, raširen na tlo (10) koji se sastoji od: gornjeg sloja (7), položenog na navedenu podlogu (4) stlačene debljine između 2 cm i 4 cm.
A mixed turf (1) as claimed in claim 5 or 6, wherein said sandy material of said upper layer (7) consists of crushed stones and sand having pH values included between 6.0 and 7.5. 
Mješoviti travnjak (1) prema zahtjevima 5 ili 6, naznačen time da navedeni pjeskoviti materijal u navedenom gornjem sloju (7) je drobljeni kamen i pijesak pH vrijednosti od 6,0 do 7,5.
A mixed turf (1) as claimed in one or more of claims 6-7, wherein said sandy material of said upper layer (7) consists of crushed stones and sand a fraction of which higher than 85% having particle sizes included between 0.05 mm and 2.00 mm. 
Mješoviti travnjak (1) prema jednom ili više zahtjeva 6-7, naznačen time da je navedeni pjeskoviti materijal u navedenom gornjem sloju (7) drobljeni kamen stlačenog granulometrijskog sastava između 0,05 i 2,00 mm za frakciju veću od 85%.
Replication-competent vaccinia virus vector that is thymidine kinase (TK)-deficient and expresses GM-CSF for use in a method of inducing oncolysis of a tumor in a human subject, wherein the method comprises administering to said subject at least 1 x 109 pfu of the vaccinia virus vector by injection into the tumor mass or tumor vasculature. 
Vektor vaccinia virusa koji se sposoban za replikaciju kojem je nedostaje timidin kinaza (TK) i koji eksprimira GM-CSF naznačen time da je za uporabu u postupku induciranja onkolize tumora kod subjekta koji je čovjek, pri čemu postupak sadrži primjenu na navedenog subjekta najmanje 1 x 109 pfu vektora vaccinia virusa pomoću injekcije u tumorsku masu ili krvne žile tumora.
The replication-competent vaccinia virus vector for use of claim 1, wherein the tumor is a brain cancer tumor, a head & neck cancer tumor, an esophageal cancer tumor, a skin cancer tumor, a lung cancer tumor, a thymic cancer tumor, a stomach cancer tumor, a colon cancer tumor, a liver cancer tumor, an ovarian cancer tumor, a uterine cancer tumor, a bladder cancer tumor, a testicular cancer tumor, a rectal cancer tumor, a breast cancer tumor, a pancreatic cancer tumor, a hepatocellular carcinoma, or a melanoma. 
Vektor vaccinia virusa koji se sposoban za replikaciju za uporabu prema zahtjevu 1, naznačen time da tumor je tumor raka mozga, tumor raka glave i vrata, tumor raka jednjaka, tumor raka kože, tumor raka pluća, tumor raka timusa, tumor raka želuca, tumor raka debelog crijeva, tumor raka jetre, tumor raka jajnika, tumor raka maternice, tumor raka mokraćnog mjehura, tumor raka testisa, tumor raka rektuma, tumor raka dojke, tumor raka gušterače, hepatocelularni karcinom, ili melanom.
The replication-competent vaccinia virus vector for use of claim 1, wherein oncolysis is induced in at least 20% of the cells in said tumor, in at least 30% of the cells in said tumor, in at least 40% of the cells in said tumor, in at least 50% of the cells in said tumor, in at least 60% of the cells in said tumor, in at least 70% of the cells in said tumor, in at least 80% of the cells in said tumor, or in at least 90% of the cells in said tumor. 
Vektor vaccinia virusa koji se sposoban za replikaciju za uporabu prema zahtjevu 1, naznačen time da je onkoliza inducirana u najmanje 20% stanica u navedenom tumoru, u najmanje 30% stanica u navedenom tumoru, u najmanje 40% stanica u navedenom tumoru, u najmanje 50% stanica u navedenom tumoru, u najmanje 60% stanica u navedenom tumoru, u najmanje 70% stanica u navedenom tumoru, u najmanje 80% stanica u navedenom tumoru, ili u najmanje 90% stanica u navedenom tumoru.
The replication-competent vaccinia virus vector for use of claim 1, wherein the tumor is multi-drug resistant. 
Vektor vaccinia virusa koji se sposoban za replikaciju za uporabu prema zahtjevu 1, naznačen time da je tumor otporan na višestruke lijekove.
The replication-competent vaccinia virus vector for use of claim 1, wherein the tumor is non-resectable prior to treatment and resectable following treatment. 
Vektor vaccinia virusa koji se sposoban za replikaciju za uporabu prema zahtjevu 1, naznačen time da tumor je ne-resektabilan prije tretmana i resektabilan poslije tretmana.
complement control polypeptide VCP; 
komplementarni kontrolni polipeptid VCP;
The replication-competent vaccinia virus vector for use of claim 13, wherein the medicament is for two or more times of administration over a period of at least 6 weeks. 
Vektor vaccinia virusa koji se sposoban za replikaciju za uporabu prema zahtjevu 13, naznačen time da je lijek za primjenu dva ili više puta tijekom perioda od najmanje 6 tjedana.
The replication-competent vaccinia virus vector for use of claim 14, wherein the medicament is administered weekly (days 1, 8, 15, 22, 29, and 36) for a total of 6 treatments or every three weeks. 
Vektor vaccinia virusa koji se sposoban za replikaciju za uporabu prema zahtjevu 14, naznačen time da se lijek primjenjuje tjedno (dani 1, 8, 15, 22, 29, i 36) kroz ukupno 6 tretmana ili svaka tri tjedna.
is chosen from the series consisting of (C3-C7)-cyc(oalkyl, and R32-CuH2u-, wherein u is an integer chosen from the series consisting of 0, 1, 2 and 3; 
je odabran iz niza koji čine (C3-C7)-cikloalkil, i R32-CuH2u-, pri čemu u je cijeli broj odabran iz niza koji čine 0, 1, 2 i 3;
is chosen from the series consisting of hydrogen and (C1-C6)-alkyl; 
je odabran iz niza koji čine vodik i (C1-C6)-alkil;
m, independently of each other number m, is an integer chosen from the series consisting of 0 and 2; 
m, međusobno neovisno broj m, je cijeli broj odabran iz niza koji čine 0 i 2;
A process for the preparation of a compound of the formula I or a physiologically acceptable salt thereof or a physiologically solvate of any of them as claimed in any one or more of claims 1 to 6, comprising reacting a compound of the formula II with a compound of the formula III, wherein the groups Ht, G, R10, R11, R30, R40, R50 and R60 in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group J in the compound of the formula II is HO-, (C1-C4)-alkyl-O- or halogen. 
Postupak za pripremanje spoja s formulom I ili neke njegove fiziološki prihvatljive soli, ili fiziološki prihvatljivog solvata bilo kojeg od njih prema bilo kojem ili više zahtjeva 1 do 6, naznačen time da sadrži reakciju spoja s formulom II sa spojem s formulom III, [image] pri čemu skupine Ht, G, R10, R11, R30, R40, R50 i R60 u spojevima s formulama II i III su definirane kao u spojevima s formulom I, a dodane funkcionalne skupine mogu biti prisutne u zaštićenom obliku ili u obliku prekursorske skupine, i skupina J u spoju s formulom II je HO-, (C1-C4)-alkil-O- ili halogen.
A pharmaceutical composition, which comprises at least one compound of the formula I as claimed in any one or more of claims 1 to 5 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time da sadrži barem jedan spoj s formulom I prema bilo kojem ili više zahtjeva od 1 do 6 ili njegovu fiziološki prihvatljivu sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih i farmaceutski prihvatljiv nosač.
Use of a compound of the formula I as claimed in any one or more of claims 1 to 6 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them for the manufacture of a medicament for the treatment of heart failure, congestive heart failure, cardiomyopathy, myocardial infarction, left ventricular dysfunction, cardiac hypertrophy, valvular heart diseases, hypertension, atherosclerosis, peripheral arterial occlusive disease, restenosis, vasvular permeability disorders, treatment of edema, thrombosis, rheumatoid arthritis, osteoarthritis, renal failure, cystic fibrosis, chronic bronchitis, chronic obstructive pulmonary disease, asthma, immunological diseases, diabetic complications, fibrotic diseases, pain, ischemia or reperfusion damage or neurodegenerative diseases, or for cardioprotection or renoprotection or as a diuretic (stand-alone treatment or in combination with established diuretics). 
Uporaba spoja s formulom I prema bilo kojem ili više zahtjeva 1 do 6 ili njegova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih naznačena time da je za proizvodnju lijeka za liječenje zatajenja srca, kongestivnog zatajenja srca, kardiomiopatija, infarkta miokarda, lijeve ventrikularne disfunkcije, srčane hipertrofije, bolesti srčanih zalistaka, hipertenzije, ateroskleroze, bolesti začepljenja perifernih arterija, restenoza, poremećaja propusnosti zalistaka, liječenja edema, tromboze, reumatoidnog artritisa, osteoartritisa, zatajenja bubrega, cistične fibroze, kroničnog bronhitisa, kronične opstruktivne plućne bolesti, astme, imunoloških bolesti, dijabetičkih komplikacija, fibroznih bolesti, boli, ishemijske ili reperfuzijske ozljede ili neurodegenerativnih bolesti, ili za zaštitu srca ili zaštitu bubrega ili kao diuretik (samostalni tretman ili tretman u kombinaciji s utvrđenim diureticima).
Composition according to any one of claims 1 to 3 comprising at least one further active ingredient selected from the group of the insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth regulators, herbicides, fertilizers, safeners and semiochemicals. 
Pripravak prema bilo kojem od zahtjeva 1 do 3 naznačen time da sadrži barem jedan dodatni aktivni sastojak koji je odabran iz skupine koju čine insekticidi, atraktanti, sterilizacijska sredstva, baktericidi, akaricidi, nematicidi, fungicidi, sredstva za regulaciju rasta, herbicidi, fertilizatori, zaštitna sredstva i semiokemikalije.
Process for preparing a compound of formula (I) comprising 
Postupak za pripremu spoja formule (I) [image] naznačen time da obuhvaća
reacting a compound of formula (II) with oxalic acid to form the oxalate salt of the compound of formula (II), wherein the reaction is carried out in ethanol or in a mixture of water and ethanol after which iso-propylacetate is added to the reaction mixture; and 
reakciju spoja s formulom (II) [image] s oksalnom kiselinom da se dobije oksalatna sol spoja s formulom (II), pri čemu se reakcija provodi u etanolu ili u smjesi vode i etanola nakon čega se u reakcijsku smjesu dodaje izo-propilacetat; i
deprotecting the compound of formula (V) using aqueous hydrochloric acid in methanol in a two-phase system to obtain the compound of formula (I). 
deprotekciju spoja s formulom (V) korištenjem vodene klorovodične kiseline u metanolu u dvofaznom sustavu da se dobije spoj s formulom (I).
A pesticide against parasite on animal, containing the anthranilamide compound or its salt as defined in any one of Claims 1 to 13, as an active ingredient. 
Pesticid, naznačen time, da kao djelatni sastojak sadrži spoj antranilamida ili sol istog kako je definirano u patentnom zahtjevu 1.
A preventive or therapeutic agent for an animal disease caused by parasite, containing the anthranilamide compound or its salt as defined in any one of Claims 1 to 13, as an active ingredient. 
Preventivno ili terapijsko sredstvo za bolesti životinja uzrokovane parazitima, naznačen time, da kao djelatni sastojak sadrži spoj antranilamida ili sol istog u skladu s patentnim zahtjevom 1.
A method for controlling a pest, which comprises applying an effective amount of the anthranilamide compound or its salt as defined in any one of Claims 1 to 13. 
Postupak za nadzor štetočina, naznačen time, da se sastoji od primjene učinkovite količine antranilamidnog spoja ili njegove soli kao što je definirano u patentnom zahtjevu 1, osim kao postupak za liječenje ljudskog ili životinjskog tijela terapijom.
and R4 each independently represent a hydrogen atom, an alkyl group, an alkenyl group, an amino group, an alkylamino group, a dialkylamino group, an aminoalkyl group, a halogenoalkyl group, an alkanoyl group, an aminoalkanoyl group, an alkylaminoalkanoyl group, an alkoxycarbonyl group, a hydroxyl group, or a mercapto group, or R3 and R4 together form an alkylene group or an alkenylene group, which may be bridged between two carbon atoms to an arbitrary position; and 
i R4 svaki neovisno predstavljaju atom vodika, alkilnu skupinu, alkenilnu skupinu, amino skupinu, alkilamino skupinu, dialkilamino skupinu, aminoalkulnu skupinu, halogenoalkilnu skupinu, alkanoilnu skupinu, aminoalkanoilnu skupinu, alkilaminoalkanoilnu skupinu, alkoksikarbonilnu skupinu, hidroksilnu skupinu ili merkapto skupinu ili R3 i R4 zajedno tvore alkilensku skupinu ili alkenilensku skupinu, koja može biti premoštena između dva ugljikova atoma na proizvoljnom položaju; a 1, m i n predstavljaju cijeli broj od 1 do 4.
The isoquinoline-6-sulfonamide derivative according to claim 1, a salt thereof, or a solvate of the derivative or the salt, wherein in Formula (1), X and Y are each independently a direct bond, NH, CH=CH, O, or S; R1 and R2 are each independently a hydrogen atom, a halogen atom, a cyano group, a C1-8 alkyl group, a halogeno C1-8 alkyl group, a C2-8 alkenyl group, a C1-8 alkoxy group, a C1-8 alkylthio group, a hydroxyl group, a mercapto group, a nitro group, a phenyl group, an amino group, or an amino C1-8 alkylthio group; R3 and R4 are each independently a hydrogen atom, a C1-8 alkyl group, a C2-8 alkenyl group, an amino group, an amino C1-8 alkyl group, a halogeno C1-8 alkyl group, a C1-8 alkylamino group, a di-C1-8 alkylamino group, a C2-8 alkanoyl group, an amino C2-8 alkanoyl group, a C1-8 alkoxycarbonyl group, a hydroxyl group, or a mercapto group, or R3 and R4 together form a bridged C1-3 alkylene group or alkenylene group; 1 and m are each independently 1 to 3; and n is 2 or 3. 
Derivat izokinolin-6-sulfonamida u skladu s patentnim zahtjevom 1, njegova sol ili solvat derivata ili soli, naznačen time, da u Formuli (1), X i Y su svaki neovisno direktna veza, NH, CH=CH, O ili S; R1 i R2su svaki neovisno atom vodika, atom halogena, cijano skupina, C1-8 alkilna skupina, halogeno C1-8 alkilna skupina, C2-8 alkenilna skupina, C1-8 alkoksi skupina, C1-8 alkiltio skupina, hidroksilna skupina, merkapto skupina, nitro skupina, fenilna skupina, amino skupina ili amino C1-8 alkiltio skupina; R3 i R4 su svaka neovisno atom vodika, C1-8 alkilna skupina, C2-8 alkenilna skupina, amino skupina, amino C1-8 alkilna skupina, halogeno C1-8 alkilna skupina, C1-8 alkilamino skupina, di-C1-8 alkilamino skupina, C2-8 alkanoilna skupina, amino C2-8 alkanoilna skupina, C1-8 alkoksikarbonilna skupina, hidroksilna skupina ili merkapto skupina ili R3 i R4 zajedno tvore premoštenu C1-3 alkilensku skupinu ili alkenilensku skupinu; 1 i m su svaki neovisno 1 do 3; a n je 2 ili 3.
A compound selected from the group consisting of the following, a salt thereof, or a solvate thereof: 
Spoj odabran iz skupine koja se sastoji od sljedećeg, njihovih soli ili njihovih solvata:
A method for preventing or treating glaucoma, cardiovascular disease, or disease or disorder caused by neurodegeneration or nerve injury, comprising administering an effective amount of a compound according to any one of claims 1 to 6. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da se koristi za prevenciju ili liječenje glaukoma, srčanožilnih bolesti ili bolesti ili poremećaja uzrokovanih neorodegeneracijom ili ozljedom živca.
A pharmaceutical composition comprising a compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable adjuvant, diluent or carrier. 
Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1 do 5, ili njegovu farmaceutski prihvatljivu sol; te farmaceutski prihvatljivo pomoćno sredstvo, razrjeđivač ili nosač.
• a modulator of chemokine receptor function; 
• modulator funkcije receptora kemokina;
A compound having formula (II): or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein: 
Spoj koji ima formulu (II): [image] ili farmaceutski prihvatljiva sol, stereoizomer ili tautomer istog, naznačen time, da:
The compound of any of claims 1 to 15 for use in treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 13 ili farmaceutski pripravak u skladu s patentnim zahtjevom 14, naznačen time, da se koristi u postupku liječenja ili sprječavanja karcinoma, upalnih stanja, imunoloških stanja, neurodegenerativnih bolesti, dijabetesa, pretilosti, neuroloških poremećaja, bolesti povezanih sa starosnom dobi ili srčanožilnih stanja.
wherein the 5-membered ring formed by carbon atom, nitrogen atom, U, T, and V is aromatic; 
pri čemu je 5-člani prsten koji formira atom ugljika, atom dušika, U, T, i V aromatski;
or R9 and R10 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; 
ili R9 i R10 zajedno sa atomom dušika na koji su spojeni formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu grupu;
or Rc" and Rd" together with the N atom to which they are attached form a 4-,5-,6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6alkyl, C1-6 haloalkyl, C1-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; 
ili Rc" i Rd" zajedno sa atomom dušika na koji su spojeni formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu grupu opcionalno supstituiranu sa 1, 2, ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 haloalkila, arila, arilalkila, heteroarila, heteroarilalkila, cikloalkila i heterocikloalkila;
The pharmaceutical composition for use according to claim 28, wherein said cancer is selected from prostate cancer, renal cancer, hepatic cancer, gastric cancer, thyroid cancer, glioblastoma, Karposi's sarcoma, Castleman's disease, melanoma, cutaneous T-cell lymphoma (CTCL), cutaneous B-cell lymphoma, Sezary syndrome, mycosis fungoides, acute lymphoblastic leukemia, and colorectal cancer. 
Spoj ili sol za upotrebu prema patentnom zahtjevu 23, naznačen time da je navedeni tumor izabran od tumora prostate, tumora bubrega, tumora jetre, tumora želuca, tumora štitnjače, glioblastoma, Karposijevog sarkojema, Castlemanove bolesti, melanoma, kožnog limfoma T-stanica (CTCL), kožnog Bell limfoma, Sezaryovog sindroma, mycosis fungoides, akutne limfoblastične leukemije, i tumora debelog crijeva.
human hematopoietic stem cells (HSCs), wherein said HSCs have a phenotype of CD34+; 
humane krvotvorne matične stanice (HKMS, engl. HSCs), gdje navedene HKMS imaju fenotip CD34+;
The composition for use according to claim 1, wherein the hFCs improve the engraftment ability of said HSCs compared to HSCs engrafted in the absence of said hFCs. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da hFS-e poboljšavaju sposobnost ugradnje navedenih HKMS-a u usporedbi s HKMS-a ugrađenim u odsutnosti navedenih hFS-a.
The composition for use according to claim 1, wherein the conditioning of the recipient includes a dose of total body irradiation (TBI), wherein the total body irradiation does not exceed 300 cGy. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da kondicioniranje primatelja uključuje dozu ukupnog tjelesnog zračenja (UTZ, engl. TBI), pri čemu ukupno tjelesno zračenje ne premašuje 300 cGy.